Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

What happened

Novo Nordisk filed a lawsuit on July 21 in U.S. District Court for the District of New Jersey, accusing Eli Lilly of running misleading advertising campaigns under the Lanham Act and state unfair competition laws. The complaint focuses on two Lilly ad campaigns: one comparing Zepbound (Lilly's obesity drug) to Wegovy (Novo's obesity drug), and another comparing Mounjaro (Lilly's diabetes drug) to Ozempic (Novo's diabetes drug).

Novo argues that a Lilly television commercial claiming Zepbound patients lost an average of 50 pounds compared to 33 pounds on Wegovy is deceptive. That comparison came from a 2023-2024 Lilly trial (SURMOUNT-5) that tested Zepbound's two highest doses against Wegovy's two lowest currently available doses. However, in March 2026, the FDA approved a new, higher dose of Wegovy. Novo's own clinical trial found that patients on the higher Wegovy dose lost an average of 47 pounds, which the company says is clinically consistent with Zepbound's results.

Novo raised similar concerns about Lilly's Mounjaro ad, which claims the drug reduced blood-sugar levels more than Ozempic. Novo says this comparison relies on a 2021 trial that predates a higher-dose version of Ozempic approved by the FDA more than four years ago.

Novo sent Lilly a cease-and-desist letter in April demanding the ads be pulled, but Lilly never formally responded. Lilly did modify its Zepbound commercial to add disclaimer language, though Novo argues the changes were insufficient. The lawsuit seeks a permanent injunction, corrective advertising, and unspecified monetary damages.

Eli Lilly responded with a statement defending its advertising, calling it truthful, transparent, and grounded in the only head-to-head, randomized clinical trial directly comparing tirzepatide (Zepbound's active ingredient) and semaglutide (Wegovy's active ingredient) in weight management. Lilly stated it will vigorously defend against the lawsuit.

Why it matters

This lawsuit highlights the escalating competitive battle in the lucrative GLP-1 weight-loss and diabetes drug market, where Novo Nordisk and Eli Lilly are the dominant players. Consumer perception and advertising play a critical role in shaping demand, as patients increasingly request specific drugs by name. There is already a perception among some consumers that Zepbound is superior to Wegovy, which could influence prescription patterns and market share.

The financial stakes are significant. Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 55% year-over-year, with Mounjaro generating $8.66 billion (+125%) and Zepbound generating $4.16 billion (+80%). In contrast, Novo Nordisk's sales fell 4%, and the company announced a 50% list-price cut for Wegovy starting in 2027. Lilly's market cap stands at roughly $1.1 trillion, compared to Novo's roughly $167 billion.

The lawsuit also raises questions about how pharmaceutical companies should advertise comparative efficacy when competitor drugs are frequently updated with new doses and formulations. If Novo prevails, Lilly could be required to pull or modify its ads and run corrective advertising, potentially affecting public perception and prescribing behavior. However, litigation is a slow process, and by the time a resolution is reached, market dynamics may have shifted further.

Bigger picture

The GLP-1 drug class, which includes both companies' obesity and diabetes treatments, has become one of the fastest-growing segments in pharmaceuticals. These drugs work by mimicking gut hormones that regulate blood sugar and appetite, leading to significant weight loss. Zepbound and Wegovy are both FDA-approved for weight loss, while Mounjaro and Ozempic are approved for Type 2 diabetes. Zepbound targets two hormones (GIP and GLP-1), while Wegovy targets only GLP-1. Zepbound is also FDA-approved to treat sleep apnea in patients with obesity, while Wegovy is FDA-approved to treat cardiovascular disease.

The legal clash comes as both companies race to expand indications, increase dosing options, and capture market share in a category that analysts expect to generate tens of billions in annual sales. The Lilly-funded study published in the New England Journal of Medicine in 2025 showed Zepbound patients lost nearly 50% more weight than Wegovy patients, though Novo contests the relevance of that comparison given subsequent regulatory approvals. Novo's higher-dose Wegovy and Wegovy HD (which demonstrated nearly 21% weight loss in trials) represent the company's effort to close the efficacy gap.

Broader industry scrutiny of pharmaceutical advertising practices may also intensify. The case tests whether head-to-head trial data remains valid for advertising purposes once competitor formulations are updated, and whether fine-print disclaimers are sufficient to avoid misleading consumers.

What to watch

Investors should monitor whether Novo Nordisk seeks a preliminary injunction in the coming days, which could force Lilly to pull or modify its advertising campaigns before a final ruling. The court's decision on whether Lilly's ads constitute false advertising under the Lanham Act will set a precedent for how pharmaceutical companies can compare competing drugs in evolving markets.

Watch for any changes in prescribing patterns or market share data for Zepbound, Wegovy, Mounjaro, and Ozempic. Real-world evidence of relative efficacy and safety, as well as patient and physician preferences, will ultimately matter more than courtroom arguments. Novo's planned 50% Wegovy list-price cut starting in 2027 may also reshape competitive dynamics.

Investors should also track whether new head-to-head trials comparing the latest approved doses of both companies' drugs are conducted or announced. Such trials could either validate or challenge the current advertising claims and influence both the lawsuit's outcome and market perceptions.